Gluthion

Quick links to important sections

Gluthion

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gluthion

Quick Facts

Property Description
Active Ingredient Glutathione (GSH)
Pharmacological Class Tripeptide, Antioxidant, Detoxifying Agent
Origin Endogenous (naturally produced in the body)
Common Use Antioxidant support, Cellular detoxification
Form (Supplemental) Oral capsule/tablet, IV injection, or other specialized forms

Gluthion is a brand-specific name for supplemental glutathione (GSH), a naturally occurring tripeptide molecule. It is synthesized by the liver and is composed of the three amino acids: L-cysteine, L-glutamic acid, and glycine. Glutathione is crucial to many vital processes, and is notably the most abundant non-protein antioxidant found in mammalian cells, maintaining high millimolar concentrations in most tissues.

It is often called the "master antioxidant" because of its essential role in protecting cells from damage caused by harmful, unstable molecules known as free radicals and reactive oxygen species, acting as an antioxidant, free radical scavenger, and detoxifying agent.

As a detoxification agent, glutathione is essential in the hepatic biotransformation process. It acts as a hydrophilic (water-loving) molecule that can bind to lipophilic (fat-loving) toxins, heavy metals, and certain drug metabolites. This reaction converts these harmful substances into forms that are inactive and more easily cleared from the body.

Gluthion, as a supplemental form, may be marketed as oral capsules, sublingual forms designed for better absorption, or as a sterile solution for intravenous (IV) administration by a healthcare provider. Depletion of the body's natural glutathione stores has been linked to increased oxidative stress and various health issues, making supplementation a common strategy to help maintain cellular defense mechanisms.

Regulatory References

  1. antioxidant, free radical scavenger, and detoxifying agent

What side effects are possible with Gluthion?

Possible side effects and safety information

The official safety information for glutathione (Gluthion), particularly regarding systemic administration, is structured around documented adverse event reports and explicit regulatory warnings, rather than standard frequency classifications.

Adverse Reaction Scope

Category Details
System-Organ Classes Involved Adverse reactions have been categorized across multiple physiological systems, including Renal and Urinary Disorders (kidney dysfunction/failure), Skin and Subcutaneous Tissue Disorders (rashes, severe mucocutaneous reactions), Gastrointestinal Disorders (nausea, vomiting, severe abdominal pain), and Vascular/Cardiovascular Disorders (hypotension, shock).
Serious Adverse Reactions Officially documented serious adverse reactions include kidney failure, severe systemic infections such as sepsis (linked to contamination), shock, and life-threatening skin conditions, specifically Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Safety Constraints and Considerations

The safety profile includes specific limitations defined by regulatory authorities:

  • Quality and Preparation Constraint: Severe and potentially fatal adverse events are linked to the use of non-pharmaceutical grade ingredients or contaminated sterile preparations, which may contain high levels of bacterial endotoxin.
  • Unauthorized Use Restriction: Regulatory bodies explicitly state that the use of injectable glutathione for purposes such as skin whitening is not an approved indication and is associated with safety risks.
  • Population-Specific Considerations: Warnings exist for specific co-administration practices, noting increased risk for complications like kidney stones when high-dose Vitamin C is used concurrently, and risks for individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

Connection to the Overall Safety Profile

The regulatory safety structure emphasizes that the most severe risks are primarily associated with the quality of the preparation and its use outside of official regulatory approval. The profile confirms that reported adverse events can occur acutely, sometimes within minutes of infusion, and involve multiple organ systems, necessitating a safety focus on product sterility and appropriate application.

Overdose and Emergency Response

The official regulatory profile for Gluthion overdose is defined by documented risks associated with high-dose intravenous administration and the use of compounded products outside of approved medical settings. These circumstances have been associated with severe systemic adverse reactions and life-threatening outcomes, rather than symptoms from a conventional oral overdose.

Documented Overdose Manifestations

Regulator-documented severe manifestations linked to unsafe use include acute signs such as chills, fever, shaking, vomiting, and potentially severe hypotension (low blood pressure) and difficulty breathing. Furthermore, warnings cite the risk of serious organ toxicities, specifically hepatic injury, renal dysfunction, and neurotoxicity. The overdose profile also includes reports of severe, potentially fatal skin conditions such as Stevens Johnson Syndrome and Toxic Epidermal Necrolysis.

When to Seek Urgent Help

Regulatory advisories emphasize that patients must seek immediate medical attention upon the onset of any side effects following administration. In cases of severe systemic reaction, hospital transfer and monitoring are required to manage the documented acute toxicities. It is noted in regulatory sources that no specific antidote is formally documented for managing Gluthion-related toxicity.

Therapeutic Uses of Gluthion

What Gluthion Treats: Main Uses and Benefits

Gluthion is commonly used to provide essential support for conditions characterized by chronic systemic imbalance, offering symptomatic assistance across several therapeutic domains. The compound is considered relevant for managing conditions like nonalcoholic fatty liver disease (NAFLD/MASLD), neurodegenerative disorders such as Parkinson's disease, and symptoms associated with compromised circulation like peripheral artery disease (PAD). This supportive therapeutic benefit helps address symptoms related to organ-specific functional stress and inflammatory states.

The primary benefit contributes to improved comfort: “Gluthion may assist with managing challenging symptoms, helping patients cope more steadily with symptom fluctuations and easing the impact on routine activities.” In clinical settings marked by heightened systemic burden, it supports general well-being during symptomatic phases.


Quick Fact: Symptomatic Support Focus

Symptom Focus Clinical Scenario Patient Benefit
Physical discomfort, fatigue, and limited movement Chronic hepatic stress, neurodegenerative conditions, or compromised circulation (PAD). Contributes to improved day-to-day comfort and helps maintain a sense of functional stability.

Eligibility and Restrictions for Use

The eligibility profile for Gluthion is defined by several regulatory constraints that outline who is permitted to use the medicine and who is formally restricted. Gluthion is contraindicated for individuals with a known allergy to the active substance. Furthermore, the inhaled formulation is contraindicated in patients with asthma due to the documented risk of causing bronchospasm.

Use during pregnancy and breastfeeding is not recommended; regulatory documentation advises avoidance because reliable safety and efficacy data are insufficient for these populations. The safety and effectiveness of general supplemental use are also not established for children, adolescents, and older adults due to limited clinical data.

Special caution is advised for certain conditions: the intravenous formulation is explicitly warned against for unapproved cosmetic purposes by national health authorities. Caution is also warranted for patients with conditions like G6PD deficiency due to the potential for complications with concomitant injectable substances. The only officially documented, approved indication for the intravenous form in some regions is as an adjunctive treatment for patients receiving cisplatin chemotherapy.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Gluthion (glutathione) is primarily defined by its role as an antioxidant and detoxification agent in the body. Official regulatory documents outline constraints related to co-administration with other medicines where the product's protective properties may affect therapeutic outcomes.


Documented Interaction Domains

Interacting Agent Category Practical Constraint and Official Context
Chemotherapeutic Agents Caution is advised with drugs requiring oxidative activity for efficacy, such as alkylating agents (e.g., cisplatin, cyclophosphamide). The product's antioxidant action may potentially reduce the intended cytotoxic effect of these cancer treatments.
Acetaminophen (Paracetamol) This product is relevant in the context of high-dose acetaminophen exposure. Official regulatory information notes its role in the detoxification process of the reactive metabolite that causes toxicity.

Official Regulatory Context

Regulatory documentation confirms a clinically significant interaction potential where the product is co-administered with certain chemotherapy medicines. The constraint is focused on maintaining the full therapeutic effectiveness of the cancer treatment, and its use is restricted or redefined in this setting.

Furthermore, some regulatory frameworks document the product's use for prophylactic purposes during chemotherapy. The product's overall interaction structure is strictly grounded in its established biochemical function related to detoxification, which necessitates cautious consideration when used alongside agents with oxidative mechanisms of action.

Mechanism of Action

Gluthion is a pharmaceutical compound that exerts its effect through the inhibition of specific enzymatic targets within the mevalonate pathway. Its primary mechanism involves binding to and inhibiting farnesyl pyrophosphate synthase (FPPS). This molecular interaction interrupts the synthesis of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), two critical lipid intermediates.

Suppression of FPP and GGPP synthesis modulates the post-translational modification (prenylation) of small GTPase signaling proteins, specifically Rho, Rac, and Rab. Since these proteins require prenylation for membrane localization and activity, Gluthion effectively prevents their functional incorporation into downstream signaling pathways. This intracellular cascade ultimately results in the disruption of the osteoclast cytoskeletal structure and the inhibition of osteoclast adhesion to the bone matrix. Consequently, the compound regulates the overall rate of bone resorption activity at the system level.

Dosage and Administration Information

How to Use Gluthion

Gluthion, as a sterile injectable solution of glutathione, is administered exclusively through parenteral routes, specifically as an Intravenous (IV) injection or infusion or an Intramuscular (IM) injection. This protocol mandates use in a controlled clinical environment under the supervision of a licensed healthcare professional.

The product is typically supplied as a lyophilized powder that requires reconstitution with a provided solvent before injection. For IV infusion, the solution requires further dilution with an appropriate fluid. Due to potential incompatibility, the reconstituted solution must not be admixed with other medicinal products.

Dosing recommendations are specific to the therapeutic context and may vary by region. When used as an adjunct to mitigate neurotoxicity during cancer treatment, the dose may be calculated based on the patient's body surface area, with regimens such as 1.5 g/m^2 administered as a single dose. For other approved uses, such as the management of severe liver disorders, the daily dose generally ranges from 600 mg to 1,200 mg and is administered daily. These regimens establish a pattern of acute, intermittent, or daily-cyclic use tied directly to the primary treatment plan. Safety and efficacy in the pediatric population have not been determined.

Recent Clinical Evidence

This overview describes the types of clinical research that have explored the use of Gluthion (glutathione) and highlights the findings and areas of uncertainty established by researchers. This information is provided to help contextualize the evidence landscape and describes the research landscape.


Evidence for Use in Liver Conditions (e.g., NAFLD/MASLD)

Research exploring Nonalcoholic Fatty Liver Disease (NAFLD) included short-term Randomized Controlled Trials (RCTs) and pilot studies. These studies monitored changes in liver enzyme biomarkers (like ALT and AST) and fat accumulation. Some trials reported measured shifts in these markers during the study period. However, evidence remains limited by short follow-up durations, and evidence remains limited for the activity of oral formulations.


Evidence for Use in Neurodegenerative Disorders (e.g., Parkinson's Disease)

Research examined Gluthion in the context of neurodegenerative disorders like Parkinson's disease using early-phase Placebo-Controlled Trials. The primary focus was to monitor changes in clinical motor symptoms using standardized functional rating scales. Research observed measured changes in motor symptom scores; yet, findings were mixed, with some changes comparable to those observed in the placebo group. Data is limited to short-term evaluations utilizing specialized administration methods.


Evidence for Use in Conditions of Compromised Circulation

Gluthion was examined in conditions like Peripheral Artery Disease (PAD) using at least one Randomized, Double-Blind, Placebo-Controlled Trial. This trial monitored acute changes in the pain-free walking distance after intravenous infusion. While a temporary increase in measured walking distance was reported, the data available are limited because the study utilized an intravenous administration route, which is typically not employed for long-term chronic use.


Overall Research Gaps and Limitations

The majority of studies conducted on Gluthion have been short-term, primarily monitoring outcomes for only three to five months, meaning long-term effects are not fully established. Data for special populations (such as specific disease severity levels) are insufficient, and a primary limitation across the evidence landscape is the modest sample sizes of many key studies, requiring further large-scale clinical trials.

Key Studies & References

  1. National Cancer Institute Drug Dictionary: Glutathione definition, mechanism and use
  2. Review: Glutathione and Hepatic Biotransformation/Detoxification pathways
  3. Glutathione in the treatment of liver diseases: review of clinical evidence and research gaps

Frequently Asked Questions (FAQ)

Common questions about Gluthion (FAQ)

Q: What is the main reason Gluthion is prescribed by doctors?

According to official regulatory documents, the only documented, approved use for the injectable form of Gluthion in some regions is as an adjunctive treatment. This means it is used alongside cisplatin chemotherapy to help mitigate related neurotoxicity. The focus of the product information is on this approved therapeutic indication.

Q: Why do people use Gluthion if they don't have the main condition it treats?

Regulatory bodies have issued explicit warnings regarding the unapproved use of injectable Gluthion for cosmetic purposes, such as skin whitening. This use is not an official indication and is associated with documented serious safety risks. Official safety constraints highlight the importance of using the product only for its approved therapeutic indications.

Q: How quickly should someone expect Gluthion to start working?

Gluthion is administered directly into a vein via IV infusion. This route of administration means the active ingredient is available for systemic action soon after administration. Clinical research has documented monitoring for acute changes in biomarkers and symptoms shortly after the infusion. Furthermore, official safety information notes that some adverse events can be reported within minutes of the infusion.

Q: Can Gluthion be taken at the same time as common pain relievers?

Official product information advises caution when Gluthion is co-administered with other medicines. The interaction profile focuses on its role in the body's detoxification process, particularly concerning the reactive metabolite produced by high-dose acetaminophen. Concerns about specific pain relievers and co-administration should be reviewed with a healthcare professional.

Q: Are there any common over-the-counter supplements that interact with Gluthion?

Official safety warnings specifically advise caution when Gluthion is used concurrently with high-dose Vitamin C. This combination has been linked to an increased risk of complications, such as the formation of kidney stones. It is standard practice to inform the healthcare professional about all supplements being taken.

Q: Is Gluthion considered a long-term or short-term treatment?

The prescribing regimens for Gluthion are generally described as acute, intermittent, or daily-cyclic, depending on the therapeutic context. Official research evidence highlights that studies on the product have typically been short-term, meaning that long-term safety and effects have not been fully established.

Q: How does Gluthion compare to generic alternatives in terms of active ingredient?

Gluthion is the brand name for the active substance, which is glutathione (GSH). Factual information confirms that the active ingredient in the branded product is chemically identical to the glutathione found in generic sterile preparations or oral supplements.

Q: What is the risk of developing a serious interaction with Gluthion?

Official documentation focuses on a clinically significant interaction potential with certain chemotherapy agents. Specifically, the product's antioxidant properties may potentially reduce the intended cytotoxic (cell-killing) effect of drugs like alkylating agents. Use of Gluthion is restricted or redefined when co-administered in this setting.

Q: How is Gluthion usually described in research publications?

In regulatory documents and research publications, the product is factually described as glutathione (GSH), a naturally occurring tripeptide molecule. It is officially classified as an antioxidant, a free radical scavenger, and a detoxifying agent, highlighting its essential role in cellular defense mechanisms.

Q: Is Gluthion suitable for people with liver or kidney issues (informational)?

Official safety information confirms that serious adverse reactions, including kidney dysfunction and kidney failure, have been reported. Furthermore, Gluthion is a detoxification agent essential for liver function, and research has explored its use in the context of liver conditions.

Q: Why do official documents list so many potential side effects for Gluthion?

Official documents list all adverse events reported across multiple organ systems, a standard regulatory requirement. The structure of the safety information emphasizes that the most severe risks, such as sepsis and kidney failure, are linked to the quality of the preparation used and its application for unapproved purposes.

Q: Is Gluthion available without a prescription in some regions?

The sterile injectable solution of Gluthion is regulated as a medicine and must be administered under the supervision of a licensed healthcare professional. In contrast, oral formulations of glutathione are widely available in many regions as non-prescription dietary supplements, which are regulated differently.

Q: Why is Gluthion only approved for certain age groups?

Official approval for Gluthion is restricted to specific age groups because the regulatory basis for approval relies on reliable clinical data. Safety and effectiveness are not established for children, adolescents, or older adults due to a lack of sufficient data in these specific populations.

Q: How reliable is the research evidence supporting Gluthion's use?

Official evidence overviews indicate that Gluthion's research landscape has limitations. The majority of studies are short-term with modest sample sizes, meaning that data on long-term effects is not fully established. Researchers note that findings require confirmation from larger-scale clinical trials.

Q: Is it common to experience mild stomach upset when first using Gluthion?

Official safety documents report Gastrointestinal Disorders, including nausea and vomiting, as adverse reactions. These effects are documented in official regulatory profiles, which note that these issues can occur acutely.

Q: Are there specific official warnings about Gluthion and operating machinery?

Adverse reactions such as dizziness and lightheadedness have been noted in safety reports. Official caution is generally advised regarding the ability to safely operate machinery if patients experience these adverse effects.

Q: Can Gluthion affect mood or behavior?

Some reports on side effects have included mention of mood changes or 'mood swings.' Any patient experiencing changes in mood or behavior should seek appropriate medical assessment.

Q: What should a patient know about Gluthion's safety profile before starting it?

The official safety profile emphasizes that key risks are associated with the quality of the preparation and using the product for unapproved indications. Severe adverse reactions, including life-threatening skin conditions (SJS/TEN) and sepsis, have been linked to the use of non-sterile or contaminated products.

Q: How is Gluthion different from a vitamin or supplement?

The sterile injectable form of Gluthion is classified and regulated as a medicine with an approved indication for use in a controlled environment. This classification distinguishes it from oral glutathione products, which are regulated as dietary supplements and do not have the same approved medical use.

Q: What common myths or misunderstandings exist about Gluthion?

The most common misunderstanding addressed by official warnings is the use of injectable Gluthion for cosmetic purposes, specifically skin whitening. Regulatory bodies explicitly state this is not an approved indication and warn the public about the severe associated safety risks.

Q: Is it normal to feel tired when starting Gluthion?

Fatigue has been mentioned in some documented reports as a possible side effect associated with the use of Gluthion, especially following the injection procedure. Any severe or persistent symptoms, including fatigue, should be evaluated by a healthcare professional.

Q: Does Gluthion have any effect on sleep patterns?

While less commonly reported than other symptoms, some adverse event reports have included mentions of sleep disturbances or changes in sleep patterns. Any significant changes in sleep should be reported to the healthcare professional administering the medication.

Q: Does Gluthion cause weight changes?

Weight gain has been noted in some rare adverse event reports associated with the use of Gluthion, especially when high doses were administered. Weight changes are not listed among the more common or severe side effect categories described in official documents.

Q: If I miss a dose of Gluthion, what is the generally accepted advice?

As an injectable product administered in a controlled environment, protocols for missed doses are explicitly outlined within the official prescribing information. Guidance regarding missed injections is provided and managed by the administering healthcare professional as part of the established treatment schedule.

Q: Is Gluthion known to affect blood sugar levels?

Some reports have mentioned the potential for Gluthion to be associated with blood sugar level fluctuations. Furthermore, its influence on insulin sensitivity has been a topic explored in related research contexts. Patients who have concerns about blood sugar fluctuations should consult with a qualified medical professional.

Q: Is Gluthion a controlled substance?

Gluthion contains glutathione, which is a naturally occurring tripeptide molecule in the body. According to general drug classifications, the substance is not typically categorized as a scheduled or controlled substance by regulatory authorities.

Q: Can Gluthion be taken with caffeine?

While specific warnings regarding caffeine are not always found on injectable drug labels, some information suggests that caffeine intake may interfere with the absorption of oral glutathione supplements.

Q: Does Gluthion interact with alcohol? (Purely descriptive question)

Glutathione is essential for detoxification processes, and alcohol consumption is known to deplete the body’s natural stores of this substance. For this reason, some sources indicate that avoiding alcohol is advisable when using Gluthion.

How should Gluthion be stored and disposed of?

How to Store and Dispose of Gluthion

Storage and disposal instructions for Gluthion (Glutathione) are defined by regulatory labeling to maintain stability and ensure safety.

Official Storage Conditions

Injectable solutions require storage under controlled refrigeration between 2 C and 8 C. The product must be protected from light and stored in its original carton. The vials must not be frozen and should be discarded if the solution contains particles or is discolored.

Stability and Child Safety

Gluthion must be stored out of the sight and reach of children and pets. For multi-dose vials, any unused portion must be discarded after the in-use shelf-life, which is often 28 days from the first puncture date.

Disposal Instructions

Unused or expired Gluthion must not be flushed down the toilet or poured into any drain. Used needles and syringes associated with the injection must be immediately placed in an FDA-cleared, puncture-resistant sharps container and disposed of according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gluthion found in:

A-Z Index: